McNeil OTC Nasalcrom three-year market exclusivity denial requested in citizen petition.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL OTC NASALCROM THREE-YEAR MARKET EXCLUSIVITY DENIAL SOUGHT in a Jan. 13 citizen petition filed by the New York City law firm Bass & Ullman on behalf of an unnamed client that intends to market its own nonprescription cromolyn sodium 4% nasal solution for the prevention and treatment of allergic rhinitis. McNeil expects to launch Nasalcrom, which was approved by FDA Jan. 3, in time for the spring allergy season ("The Tan Sheet" Jan. 13, p. 1).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning